Business and Industry

Benzinga

2021-09-14

Cybin Inc. Likely To Benefit From New Research Touting Psilocybin Mental Health Treatments

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Check it out!

Psychedelic Science 2025: Set and (Re)Setting

For its fifth installment, Psychedelic Science 2025 returned to Denver, offering three days of big ideas, heartfelt community, and some noticeable shifts in the psychedelic space. After the usual chaos of delayed flights and travel drama on Tuesday, we shared a collective sigh of relief as we finally arrived at the Colorado Convention Center, a mile high and ready to dive in.

Colorado’s Approach to Psychedelic-Assisted Therapy: An Evolution in Mental Health Care

Elizabeth Nielson, co-founder of Fluence, offers thoughts on the roll out of the 2025 psychedelic therapy program in Colorado and the opportunities it offers for mental health professionals.

Mindstate Uses AI to Design “Next-Gen” Psychedelics Combined With 5-MeO-MiPT

Mindstate Design Labs has received approval for a Phase 1 clinical trial to investigate the use of its formulation of 5-MeO-MiPT which it hopes to combine with other drugs to target precise serotonin receptors and create future psychotropic therapies.

The Psychedelic Underground’s Future Is in Consumer Packaged Goods

Let‚Äôs not kid ourselves: medical access is merely a stepping stone to legality.

Offshore Ibogaine Clinics In Mexico, Portugal, and Brazil

In part one of a series of articles on ibogaine clinics, researcher Leonard Pickard looks at the history and treatment protocols of clinics in Mexico, Brazil and Portugal.